Petros Giovanis1,1, Graziano Pianezze2,2, Valter Vincenzi3,3, Carla Manuppelli3,3, Massimo Boaretto3,3, Davide Pastorelli1,1. 1. Medical Oncology Unit, City Hospital of Feltre, Via Bagnols Sul Ceze 3, 32032, Ulss 1 Dolomiti, Feltre, Italy. 2. Research Lab, City Hospital of Belluno, Belluno, Ulss 1 Dolomiti, Italy. 3. Internal Medicine & Hepatology, City Hospital of Belluno, Belluno, Ulss 1 Dolomiti, Italy.
Abstract
AIM: We investigated the behavior of circulating endothelial cells (CEC) in patients with hepatocellular carcinoma (HCC) receiving sorafenib, and whether CEC levels were associated with time to progression (TTP). MATERIALS & METHODS: CECs in advanced HCC patients receiving sorafenib were counted at baseline and every 4 weeks. RESULTS: Twenty four HCC patients were enrolled in the study. Median TTP was 3.2 months (1-6). Median baseline CEC levels were 67 cells/ml, with an increase of 169.8% after 4 weeks of treatment. Any time CEC levels in patients with a TTP lower than 4 months were higher, but not statistically significant, compared with those in patients with TTP more than 4 months. CONCLUSION: Treatment with sorafenib changed CEC levels in HCC patients.
AIM: We investigated the behavior of circulating endothelial cells (CEC) in patients with hepatocellular carcinoma (HCC) receiving sorafenib, and whether CEC levels were associated with time to progression (TTP). MATERIALS & METHODS: CECs in advanced HCC patients receiving sorafenib were counted at baseline and every 4 weeks. RESULTS: Twenty four HCC patients were enrolled in the study. Median TTP was 3.2 months (1-6). Median baseline CEC levels were 67 cells/ml, with an increase of 169.8% after 4 weeks of treatment. Any time CEC levels in patients with a TTP lower than 4 months were higher, but not statistically significant, compared with those in patients with TTP more than 4 months. CONCLUSION: Treatment with sorafenib changed CEC levels in HCC patients.
Authors: T Asahara; H Masuda; T Takahashi; C Kalka; C Pastore; M Silver; M Kearne; M Magner; J M Isner Journal: Circ Res Date: 1999-08-06 Impact factor: 17.367
Authors: Abby B Siegel; Anthony B El-Khoueiry; Richard S Finn; Katherine A Guthrie; Abhishek Goyal; Alan P Venook; Charles D Blanke; Elizabeth C Verna; Lorna Dove; Jean Emond; Tomoaki Kato; Benjamin Samstein; Ronald Busuttil; Helen Remotti; Amy Coffey; Robert S Brown Journal: Liver Cancer Date: 2015-03 Impact factor: 11.740
Authors: Ton J Rabelink; Hetty C de Boer; Eelco J P de Koning; Anton-Jan van Zonneveld Journal: Arterioscler Thromb Vasc Biol Date: 2004-03-04 Impact factor: 8.311
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Andrew X Zhu; Dushyant V Sahani; Dan G Duda; Emmanuelle di Tomaso; Marek Ancukiewicz; Onofrio A Catalano; Vivek Sindhwani; Lawrence S Blaszkowsky; Sam S Yoon; Johanna Lahdenranta; Pankaj Bhargava; Jeffrey Meyerhardt; Jeffrey W Clark; Eunice L Kwak; Aram F Hezel; Rebecca Miksad; Thomas A Abrams; Peter C Enzinger; Charles S Fuchs; David P Ryan; Rakesh K Jain Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544
Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245